ClinicalTrials.gg
CompletedNCT07543380Updated Sep 24, 2026

A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease.

A Phase 3 interventional study of RSVpreF in Respiratory Syncytial Virus (RSV), sponsored by Pfizer. Completed at 5 sites in Japan. Open to participants aged 18 Years to 59 Years. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
130
Allocation
Not applicable
Ages
18 Years to 59 Years
Sex
All
01

Study summary

The purpose of the study is to learn about the immune response after a RSVpreF vaccination. This study is being conducted in Japan. RSV is a common virus that can cause infections of the lungs and airways.

The study is seeking participants who are:

  • 18 to 59 years of age
  • adults with health condition(s) that can put them at an increased risk of severe RSV disease

It will also learn about the safety of RSVpreF vaccination. The study lasts about 2 months. Adults need to visit the research site at least 2 times. The participant will receive a phone call 2 months after vaccination for health checks.

Read the detailed description

This is a Phase 3, multicenter, single-arm, open-label study that will assess the safety, tolerability, and immunogenicity of Pfizer's RSVpreF in adults 18 to 59 years of age considered to be at high risk of RSV disease due to certain chronic medical conditions in Japan.

Approximately 130 participants 18 to 59 years of age considered at high risk of RSV disease due to certain chronic medical conditions will be enrolled to receive RSVpreF.

The total duration of trial participation for each participant will be 2 months.

After screening and confirmation of eligibility, a prevaccination blood sample will be collected for immunogenicity assessments and a single dose of study intervention (RSVpreF) will be administered.

Participants will report daily reactogenicity data using an electronic device for 7-days or until resolution.

Participants will return approximately 1 month later for a follow-up blood draw for immunogenicity assessments and collection of safety information.

A telephone follow-up visit will be conducted approximately 2 months after vaccination to collect safety information.

02

Conditions studied

  • Respiratory Syncytial Virus (RSV)

Keywords

  • RESPIRATORY SYNCYTIAL VIRUS (RSV)
  • ADULTS AT HIGH RISK
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Underlying health condition(s) that can put the participant at an increased risk of severe RSV/complications including chronic lung , heart, kidney, liver, nervous system, blood, or metabolic diseases

Key Exclusion Criteria:

  • Received any kind of RSV vaccine before participating in this study
  • Determined as not eligible by the investigator based on the participant's past and present health condition(s), medication(s) and treatment(s)

Please refer to the study contact for further eligibility details.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
130 participants (actual)

Study arms

  • Experimental
    RSVpreF

    RSV Vaccine

    Biological: RSVpreF

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of participants reporting prompted local reactions within 7 days following investigational product administration

    Describe prompted local reactions following investigational product administration

    Time frame: Day 7

  2. Percentage of participants reporting prompted systemic events within 7 days following investigational product administration

    Describe prompted systemic events following investigational product administration

    Time frame: Day 7

  3. Percentage of participants reporting adverse events (AEs) through 1 month following investigational product administration

    Describe AEs occurring through 1 month following administration of investigational product

    Time frame: 1 month after vaccination

  4. Percentage of participants reporting serious adverse events (SAEs) throughout the study

    Describe SAEs through 2 months following administration of investigational product

    Time frame: 2 months after vaccination

  5. Geometric Mean Titer (GMT) ratio (GMR) , estimated by the ratio of the GMTs for RSV subgroup A (RSV A) and RSV subgroup B (RSV B) neutralizing titers (NTs) with RSVpreF in this study's participants to that in Study C3671013 Japanese older adults

    Demonstrate that the immune responses to RSVpreF in this study participant are similar to those in Study C3671013 Japanese older adults

    Time frame: 1 month after vaccination

Secondary outcomes

  1. GMT of NTs for RSV A and RSV B

    Describe the immune responses to RSVpreF with GMT of NTs for RSV A and RSV B before vaccination and at 1 month after vaccination.

    Time frame: 1 month after vaccination

  2. Geometric mean fold rise (GMFR) of NTs for RSV A and RSV B

    Describe the immune responses to RSVpreF with GMFR of NTs for RSV A and RSV B from before vaccination to 1 month after vaccination.

    Time frame: 1 month after vaccination

  3. Seroresponse rate of NTs for RSV A and RSV B

    Describe the immune responses to RSVpreF with seroresponse rate of NTs for RSV A and RSV B at 1 month after vaccination. Seroresponse is defined as a postvaccination NT ≥4 times the lower limit of quantitation (LLOQ) if the baseline titer is below the LLOQ; or a ≥

    Time frame: 1 month after vaccination

07

Study locations

5 sites
  • Tsuchiura Beryl Clinic
    Tsuchiura, Ibaraki 300-0062, Japan
  • Nihonbashi Sakura Clinic
    Chuo-ku, Tokyo 103-0025, Japan
  • Tokyo-Eki Center-building Clinic
    Chuo-ku, Tokyo 103-0027, Japan
  • Fukuwa Clinic
    Chuo-ku, Tokyo 104-0031, Japan
  • Tenjin Sogo Clinic
    Fukuoka, 810-0021, Japan
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2026 to primary completion in Aug 2026, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2026
First posted
Apr 21, 2026
StartActual
May 11, 2026
Primary completionActual
Aug 25, 2026
CompletionActual
Aug 25, 2026
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07543380
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 21, 2026
Start date
May 11, 2026
Primary completion
Aug 25, 2026
Completion
Aug 25, 2026
Last update
Sep 24, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abrysvo

Start the discussion